S1P1 Receptor Modulators for Selective Signal Transduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions mediated by sphingosine-1-phosphate receptor activation lack effective modulators that can selectively target specific receptor subtypes, leading to non-specific effects and potential side effects.
Innovation Solution
Development of compounds that modulate the S1P1 subtype of the sphingosine-1-phosphate receptor, including both orthosteric and allosteric agonists, which can selectively activate the receptor for signal transduction without requiring a sub-maximal concentration of the natural ligand.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If non-specific S1P receptor modulators are used, then broader receptor coverage is achieved, but selectivity and reduction of side effects deteriorate
Solution Approach 1:
The patent segments the S1P receptor into five distinct subtypes (S1P1-5) and develops modulators that can be selectively targeted to specific subtypes. This segmentation allows for precise control over which receptor subtype is activated, thereby improving selectivity and reducing side effects while maintaining the ability to cover specific therapeutic indications.
Solution Approach 2:
The patent applies local quality by developing modulators with specific structural features that enable selective binding to particular S1P receptor subtypes. Each modulator is designed with specific molecular characteristics that confer affinity for a designated receptor subtype, allowing different regions of the receptor family to be activated selectively based on therapeutic needs.
2Reliability
If conventional S1P receptor modulators are used, then therapeutic effect is achieved, but side effects increase due to lack of specificity
Solution Approach 1:
By segmenting the receptor into subtypes and developing selective modulators for each, the patent maintains reliable therapeutic effects through targeted activation while minimizing side effects that arise from non-specific receptor activation. Each modulator is designed to activate only the intended receptor subtype, reducing harmful effects on other receptor systems.
Solution Approach 2:
The patent converts the potential harm of non-specific receptor activation into a benefit by using structural modifications in the modulator molecules to achieve selective binding. The molecular structures are designed so that only the desired receptor subtypes are activated, transforming what would be harmful non-specific effects into beneficial specific effects.
3Manufacturing precision
If selective S1P1 modulators are developed, then specificity and reduced side effects are achieved, but device complexity increases
Solution Approach 1:
The patent applies parameter changes by modifying molecular parameters such as substituent groups, stereochemistry, and molecular size in the modulator structures. These parameter changes enable selective binding to S1P1 receptor while maintaining manageable molecular complexity. The structural modifications are optimized to achieve the desired selectivity without excessive complexity in the molecular design.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds provide selective modulation of the S1P1 receptor, offering targeted therapeutic effects with reduced side effects and improved specificity for conditions where S1P1 activation is medically indicated.
Implementation Method 1
The S1P1/EDGi receptor is a G-protein coupled receptor (GPCR) and is a member of the endothelial cell differentiation gene (EDG) receptor family. Like all GPCRs, ligation of the receptor propagates second messenger signals via activation of G-proteins (alpha, beta and gamma).
Data Source
AI summary
Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable salt, homolog, hydrate or solvate thereof, wherein R is as defined herein. Such compounds serve as modulators of the sphingosine-1-phosphate receptor, and have utility for treatment of a malcondition for which activation of this receptor is medically indicated.